Back to Search

VRTX

Vertex Pharmaceuticals Inc
Data: 2026-09-11
$515.44
Price
0.17%
Change
$560.25
52W High
$374.17
52W Low
Full AI Analysis Buy/Sell Forecast Trendline Why Moving Charts Options
Analyzing positioning… Options positioning — based on yesterday's biggest open-interest changes See the chart Institutional flows
Track record
signal day → next-day price move
Quick Stats
Sep 11, 2026

38.2

AI Score

SELL

0.75

Volume Ratio

Nov 02, 2026

Next Earnings

16

+ve Days (30d)

14

-ve Days (30d)

VRTX Price vs Max Options Open Interest

How to read this: the line is the stock price; the bars show where the most option open interest sits each day. Strikes with heavy open interest often act as magnets or barriers for price ("max pain" zones). Scroll right for the most recent days.

VRTX Max Change In Options Open Interest

How to read this: each bar is the option contract whose open interest changed the most yesterday. Green bars = new positions being opened (conviction building at that strike); red bars = positions being closed. Call builds above the current price suggest upside bets; put builds below it suggest hedging or downside bets.

VRTX Options - Sort by Max open Interest (near term)

13th September 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

VRTX Daily Out of Money Options - Sort by Max open Interest (near term)

13th September 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

VRTX Daily In the Money Options - Sort by Max open Interest (near term)

13th September 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

VRTX Most Active Options by Volume(near term)

13th September 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI		 Ask PC Delta Vega Volatility % change Track
VRTX Technical Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select an indicator above — it will be added as a pane under the price chart with aligned dates.

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

VRTX Stock Summary

Last updated Sep 11, 2026

VRTX is currently trading at $515.44, positioned above its 200-day moving average of $468.0, indicating a long-term uptrend. The stock has a 52-week range of $374.17 to $560.25.

Technical Analysis: The 50-day moving average stands at $510.65, which is below the current price, signaling bullish near-term momentum. The RSI (Relative Strength Index) reads 44.054, suggesting the stock is neutral with balanced momentum.

Money Flow Indicators: The Chaikin Money Flow (20-day) is 0.06, which is positive, indicating accumulation by institutional investors. Our AI-powered investment score rates VRTX at 38.2/100 with a SELL recommendation.

VRTX (Vertex Pharmaceuticals Inc) Indicators

Last updated Sep 11, 2026

Indicator Value
RSI(14) 44.054
CMF (20) 0.06
ROC (10) -5.864
ADX (14) 29.891
Indicator Value
MACD (12,26,9) 5.195
AROONOSC (14) -35.714
WILLAMS %R (14) -92.506
MFI (14) 31.641

VRTX Candlestick Patterns

Validated patterns fired in the last 10 sessions. Hit rate = how often price moved in the signal's direction within 5 trading days (backtest: 2.7M signals, 3,500 liquid stocks, Feb 2025–Sep 2026). Baseline: a random stock closes higher 5 days later 53% of the time. Click a row to see the candle on the chart.

Date Pattern Signal 5-Day Hit Rate Edge vs Baseline Sample
Sep 09 Inverted Hammer Bullish 56.4% +3.4 pts 19834

These are statistical tilts, not standalone trade setups. Only patterns with a measured edge are shown — roughly 50 of 60 textbook patterns showed no edge and are hidden.

Vertex Pharmaceuticals Inc is above both the 50 Day and 200 Day SMA which is considered Bullish.

VRTX Moving Averages Analysis

Vertex Pharmaceuticals Inc has been above 50 day sma 1 times in last 30 days. Last time it was above 50 day sma was on Sep 11, 2026

Vertex Pharmaceuticals Inc has been above 200 day sma 1 times in last 30 days. Last time it was above 200 day sma was on Sep 11, 2026

VRTX (Vertex Pharmaceuticals Inc) Simple Moving Averages

Moving Averages are last updated Sep 11, 2026

Days MA
10 537.47
20 537.99
30 524.9
50 510.65
100 477.87
200 468.0

VRTX Fundamental Analysis

P/E (Forward) 24.3309
P/E (Trailing) 30.3934
Market Cap ($) 130.4 billion
Earnings/Share ($) 16.93
Net Profit Margin (%) 0.35
Dividend/Share ($) --
EPS Estimate Current Year ($) 16.0236
EPS Estimate Next Year ($) 20.1329
WallStreet Target Price ($) 569.19
Most Recent Quarter

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.